Risankizumab, an IL-23 inhibitor, for ankylosing...

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Baeten, Dominique, Østergaard, Mikkel, Wei, James Cheng-Chung, Sieper, Joachim, Järvinen, Pentti, Tam, Lai-Shan, Salvarani, Carlo, Kim, Tae-Hwan, Solinger, Alan, Datsenko, Yakov, Pamulapati, Chandrase
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
77
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2018-213328
Date:
September, 2018
File:
PDF, 1.27 MB
english, 2018
Conversion to is in progress
Conversion to is failed